Trade iBio, Inc. - IBIO CFD
Add to favourite- Summary
- Historical Data
Spread | 0.1260 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024846% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002624% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.001 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 2.747 |
Open | 2.707 |
1-Year Change | 857.89% |
Day's Range | 2.707 - 2.927 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 25, 2024 | 2.7770 | 0.0700 | 2.59% | 2.7070 | 2.9270 | 2.6870 |
Oct 24, 2024 | 2.7470 | 0.0800 | 3.00% | 2.6670 | 2.7970 | 2.6070 |
Oct 23, 2024 | 2.7170 | -0.0400 | -1.45% | 2.7570 | 2.8270 | 2.6770 |
Oct 22, 2024 | 2.7470 | -0.2600 | -8.65% | 3.0070 | 3.0770 | 2.6170 |
Oct 21, 2024 | 3.0270 | 0.2800 | 10.19% | 2.7470 | 3.1070 | 2.6870 |
Oct 18, 2024 | 2.8170 | 0.1600 | 6.02% | 2.6570 | 2.9670 | 2.6570 |
Oct 17, 2024 | 2.8270 | 0.0800 | 2.91% | 2.7470 | 2.8470 | 2.7170 |
Oct 16, 2024 | 2.8170 | 0.0600 | 2.18% | 2.7570 | 2.9970 | 2.6770 |
Oct 15, 2024 | 2.7670 | 0.2500 | 9.93% | 2.5170 | 2.8970 | 2.5170 |
Oct 14, 2024 | 2.4670 | -0.1500 | -5.73% | 2.6170 | 2.6570 | 2.4570 |
Oct 11, 2024 | 2.5770 | 0.0800 | 3.20% | 2.4970 | 2.7670 | 2.4970 |
Oct 10, 2024 | 2.5670 | -0.2800 | -9.83% | 2.8470 | 2.8670 | 2.5070 |
Oct 9, 2024 | 2.7870 | 0.3400 | 13.89% | 2.4470 | 2.8470 | 2.4470 |
Oct 8, 2024 | 2.6170 | -0.0400 | -1.51% | 2.6570 | 2.6670 | 2.4170 |
Oct 7, 2024 | 2.5770 | 0.0400 | 1.58% | 2.5370 | 2.7370 | 2.2170 |
Oct 4, 2024 | 2.1670 | 0.0100 | 0.46% | 2.1570 | 2.2870 | 2.0270 |
Oct 3, 2024 | 2.2370 | 0.2300 | 11.46% | 2.0070 | 2.2870 | 2.0070 |
Oct 2, 2024 | 2.1770 | 0.0000 | 0.00% | 2.1770 | 2.3070 | 2.1670 |
Oct 1, 2024 | 2.2370 | 0.0400 | 1.82% | 2.1970 | 2.2770 | 2.0870 |
Sep 30, 2024 | 2.1170 | 0.2100 | 11.01% | 1.9070 | 2.1870 | 1.9070 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
iBio, Inc. Company profile
iBio is a biopharmaceutical company behind the FastPharming System that helps with drug development “from concept to clinic”.
Headquartered in Texas, iBio was founded in 2008 and operates in biopharmaceuticals and bioprocessing segments along with its subsidiary, iBio CDMO LLC.
iBio’s main product is the FastPharming System, which has helped produce monoclonal antibodies, subunit vaccines, cytokines and other recombinant proteins, according to the company’s site.
iBio has also built the Glycaneering Development Services, which provides “greater control over the glycosylation of complex biopharmaceuticals''.
The company operates in the fields of oncology, fibrotic and infectious diseases.
The company’s development and manufacturing services deliver fast, scalable and sustainable solutions, enabling iBio to draw a licence agreement with Planet Biotechnology, and collaboration agreements with CC-Pharming Ltd, Safi BioSolutions and several other companies to develop therapeutic solutions.
The company went public in 2020 on the NYSE American. iBio, Inc. stock trades under the ticker symbol IBIO.
Check out the IBIO price history and today’s share value at Capital.com. Always stay on top of the latest price developments with our live IBIO stock chart.
Industry: | Construction & Engineering (NEC) |
11740 Katy Fwy
Energy Tower Iii, 11Th Floor
HOUSTON
TEXAS 77079
US
News
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024Gold markets to trade
Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.
08:00, 21 October 2024US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com